Canine Respiratory Virus: Diagnostic and Management Considerations

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Key Takeaways

• Diagnostic Window and Modalities: Viral shedding typically peaks 3-7 days post-onset, making early sampling crucial for maximizing sensitivity. RT-PCR on deep nasal or oropharyngeal swabs is the primary antemortem diagnostic, while point-of-care antigen tests are best for rapid screening in outbreak settings due to variable sensitivity.
• Primary Viral Agents and Clinical Overlap: Key viral pathogens include canine influenza virus (H3N8, H3N2), canine distemper virus, canine parainfluenza virus, canine adenovirus type 2, canine respiratory coronavirus, canine pneumovirus, and canine herpesvirus, all presenting with overlapping respiratory signs that necessitate laboratory confirmation.
• Risk Factors and Disease Severity: Puppies, geriatric dogs, and brachycephalic breeds are at higher risk for severe disease due to immature or compromised immune systems and anatomical predispositions affecting airway clearance and resistance.
• Transmission and Biosecurity: Respiratory viruses spread via aerosolized droplets and fomites; canine influenza virus can survive on surfaces for up to 48 hours, emphasizing the need for strict isolation, dedicated equipment, and disinfection with enveloped virus-active agents.
• Management Principles: Supportive care is paramount for uncomplicated viral infections; antimicrobial therapy is reserved for secondary bacterial pneumonia, indicated by persistent fever, radiographic consolidation, or cytologic evidence of septic inflammation.
• Complications and Long-Term Sequelae: Recognized complications include secondary bacterial pneumonia, chronic airway inflammation (potentially linked to persistent viral RNA remnants), and rare neurologic involvement, requiring vigilant monitoring and advanced diagnostics for early detection.

Viral respiratory infections in dogs present a recurring diagnostic challenge in small animal practice. Clinical signs overlap substantially across viral, bacterial, and noninfectious causes, and the available point-of-care tests vary widely in sensitivity depending on the pathogen, sampling site, and disease stage. This article reviews the principal canine respiratory viruses, their pathogenesis and clinical features, and the evidence base for diagnostic test selection and management decisions. It is written for practicing veterinarians seeking a structured approach to suspected viral respiratory disease, from initial case assessment through treatment and outbreak control.

The article addresses several practical questions. Which viruses should be considered in a given clinical context, and how do their epidemiological patterns differ? What sampling methods and test modalities offer the best diagnostic yield at different stages of illness? When is empirical therapy appropriate, and what supportive measures are supported by evidence? The discussion focuses on viral causes, with bacterial pathogens considered only where they influence diagnostic interpretation or treatment decisions.

At a Glance

Viral Pathogens and Their Clinical Signatures

Canine Influenza Virus

Canine influenza virus (CIV) is an orthomyxovirus with two recognized subtypes in dogs: H3N8, which emerged in the United States in 2004, and H3N2, which originated from an avian reservoir and was first identified in Asia. Both subtypes cause acute respiratory disease with high morbidity and low mortality. The virus targets ciliated respiratory epithelium, causing necrotizing tracheobronchitis and bronchointerstitial pneumonia. Viral shedding typically begins 24 to 48 hours after exposure, peaks around day 3 to 5, and may persist for up to 2 weeks in some animals.

Clinical signs range from subclinical infection to severe pneumonia. The classic presentation is a harsh, dry cough that persists for 10 to 21 days, often accompanied by serous nasal discharge and low-grade fever. A subset of dogs develops hemorrhagic pneumonia with high fever, tachypnea, and lethargy. Mortality is generally below 10 percent, with the highest risk in puppies, geriatric dogs, and brachycephalic breeds. Co-infection with bacterial pathogens, particularly Bordetella bronchiseptica and Streptococcus equi subsp. zooepidemicus, worsens outcomes. The pathogenesis of severe disease involves both direct viral cytopathology and host inflammatory responses, a pattern observed across respiratory viruses in other species Influenza A virus infection causes chronic lung disease linked to sites of active viral RNA remnants.

Canine Distemper Virus

Canine distemper virus (CDV) is a paramyxovirus that causes multisystemic disease, with respiratory signs often preceding or accompanying neurologic and gastrointestinal manifestations. The virus replicates in lymphoid tissue before spreading to epithelial surfaces and the central nervous system. Respiratory signs include serous to mucopurulent nasal discharge, cough, and tachypnea. Secondary bacterial pneumonia is common. Diagnosis relies on PCR of conjunctival, nasal, or pharyngeal swabs, or on immunohistochemistry of postmortem tissues. Vaccination status is critical to interpretation, as modified-live vaccines can produce transient positive PCR results.

Other Viral Agents

Canine parainfluenza virus (CPIV) is a common component of the canine infectious respiratory disease complex (CIRDC). It causes mild tracheobronchitis, typically as part of a polymicrobial infection. Canine adenovirus type 2 (CAV-2) similarly contributes to CIRDC and can cause more severe disease in young puppies. Canine respiratory coronavirus (CRCoV) is a betacoronavirus associated with mild respiratory disease, often in kenneled populations. Canine pneumovirus and canine herpesvirus are less common but should be considered in outbreak settings and neonatal disease, respectively.

The clinical overlap among these agents means that etiologic diagnosis requires laboratory confirmation. Empirical treatment for suspected viral respiratory disease is reasonable in mild cases, but diagnostic testing is indicated when outbreaks occur, when disease is severe or progressive, or when co-infection with bacterial pathogens is suspected. The differential production of proinflammatory cytokines across respiratory viruses, documented in experimental models, suggests that the host inflammatory response varies by pathogen and may influence clinical severity Differential production of proinflammatory cytokines in the pig lung during different respiratory virus infections.

Host Factors and Disease Severity

Age and Immune Status

Puppies and geriatric dogs are at increased risk of severe disease from most respiratory viruses. Maternal antibody interference can render vaccination ineffective in young puppies, leaving a window of susceptibility. Immunosuppressed dogs, whether from disease or drug therapy, shed virus longer and may present with atypical clinical signs.

Breed and Anatomic Factors

Brachycephalic breeds have impaired mucociliary clearance and increased airway resistance, predisposing them to more severe clinical signs and secondary bacterial infection. Their anatomic features also complicate sample collection and may reduce the diagnostic yield of nasal swabs.

Sex Differences

Experimental and clinical data from human respiratory virus infections demonstrate that biological sex influences disease outcomes, with patterns varying by age and reproductive status Sex differences in respiratory viral pathogenesis and treatments. Comparable data in dogs are limited, but clinicians should recognize that host factors beyond pathogen identity contribute to disease expression.

Transmission and Environmental Persistence

Respiratory viruses spread primarily through aerosolized droplets and fomites. Canine influenza virus survives on surfaces for up to 48 hours and on hands for up to 12 hours, making environmental contamination a significant transmission route in veterinary hospitals and kennels. CRCoV and CPIV are similarly resilient. Effective infection control requires isolation of affected dogs, dedicated equipment, and disinfection with agents active against enveloped viruses.

The incubation period varies by agent, ranging from 1 to 3 days for CIV to up to 2 weeks for CDV. This variation complicates outbreak management, as exposed dogs may be infectious before clinical signs appear. The WOAH terrestrial animal health standards provide general principles for surveillance and reporting that can inform outbreak protocols, although specific canine respiratory viruses are not individually notifiable in most jurisdictions.

Diagnostic Reasoning Framework

When to Test

Testing is not required for every dog with respiratory signs. Mild, self-limiting cough in a vaccinated, otherwise healthy adult dog with known exposure to a respiratory outbreak may be managed symptomatically. Testing is indicated when any of the following apply: severe or progressive clinical signs, suspected outbreak in a kennel or shelter, exposure to a known infected dog, immunocompromised host, or need to inform isolation protocols in a multi-dog household or hospital setting.

Test Selection and Timing

PCR is the most sensitive antemortem diagnostic for most canine respiratory viruses. Sample selection depends on the suspected agent. Deep nasal swabs or oropharyngeal swabs are appropriate for CIV, CPIV, and CRCoV. Conjunctival swabs increase yield for CDV. Samples should be collected within the first 3 to 5 days of clinical signs, when viral shedding is highest. Serology has a role in retrospective diagnosis and outbreak investigation, using paired acute and convalescent samples collected 2 to 3 weeks apart.

Point-of-care antigen tests for CIV exist but have variable sensitivity, particularly in dogs with low viral loads. They are most useful in outbreak settings where a rapid preliminary diagnosis can guide isolation decisions. Negative antigen test results do not exclude infection, and PCR confirmation should follow when clinical decisions depend on the result.

Interpretation Pitfalls

Vaccination can confound PCR results for CDV and CAV-2. Recent modified-live vaccination may produce positive PCR results for up to 3 weeks. A positive PCR result in a vaccinated dog with respiratory signs therefore requires correlation with clinical findings and vaccination history. Conversely, false-negative PCR results occur when sampling is delayed, when the swab does not contact infected epithelium, or when the dog is shedding below the assay's detection limit.

Diagnostic Sampling and Laboratory Testing

The diagnostic plan for suspected viral respiratory disease in dogs should balance diagnostic yield, patient stability, cost, and turnaround time. Sampling site and technique determine which pathogens can be detected and how reliably.

Sample Types and Collection Methods

Nasal and oropharyngeal swabs are the most practical first-line samples. Use flocked swabs with plastic shafts, as cotton-tipped wooden swabs can inhibit PCR. Collect from the nasal cavity and caudal oropharynx, combine both sites into one transport tube, and place the sample in viral transport medium or sterile saline if transport medium is unavailable. Refrigerate samples and ship on cold packs, freeze only if processing will be delayed beyond 48 hours.

Deep nasal flush or transtracheal wash is indicated when upper airway sampling is negative but clinical suspicion remains high, particularly for lower airway involvement. These techniques require sedation or anesthesia and carry a small risk of bronchospasm or hemorrhage. They are preferred when the goal is to distinguish viral from bacterial or fungal disease, because cytology and culture can be performed on the same sample.

Bronchoalveolar lavage (BAL) provides the most representative sample of the lower airways. It is reserved for patients with diffuse interstitial or alveolar patterns on thoracic radiographs, those failing empirical therapy, or those with suspected co-infections. BAL fluid should be split: one aliquot for PCR, one for cytology, and one for aerobic culture. The cytology of viral pneumonia typically shows mixed inflammation with a neutrophilic or mononuclear predominance, but these findings are not specific enough to confirm a viral etiology.

Whole blood and urine are useful for canine distemper virus detection. Antigen RT-PCR on whole blood, urine, or conjunctival swabs can identify systemic spread, and paired serology remains valuable in vaccinated dogs where antigen detection is confounded by vaccine-strain virus.

Point-of-Care Testing

Rapid antigen tests for canine influenza virus exist but have limited sensitivity compared with PCR. A negative point-of-care test does not exclude infection, particularly in the first 24 to 48 hours after exposure or after day 5 of clinical signs when viral shedding declines. These tests are best used as screening tools in outbreak settings where multiple dogs are affected and a rapid presumptive diagnosis guides isolation protocols while confirmatory PCR is pending.

Molecular Testing

Real-time reverse transcription PCR (RT-PCR) is the reference standard for diagnosing canine influenza virus, canine distemper virus, and respiratory coronaviruses. Panels that test for multiple pathogens simultaneously are commercially available and are preferred when the clinical presentation does not narrow the differential. Sample quality is the most common cause of false-negative PCR results. A swab that samples only saliva or fur contamination will frequently miss nasal viral shedding.

Quantitative PCR (qPCR) adds limited clinical value for most canine respiratory viruses because viral load does not correlate reliably with disease severity or outcome. Its main use is serial monitoring of shedding in shelter or kennel outbreaks, where declining cycle threshold values guide decisions about releasing isolation cohorts.

Interpreting Results in Context

A positive PCR result confirms the presence of viral nucleic acid but does not prove causation. Canine respiratory coronavirus and parainfluenza virus can be detected in clinically healthy dogs, and subclinical shedding is well documented. Interpret positive results alongside clinical signs, radiographic findings, and the presence or absence of co-infections.

A negative PCR result does not exclude a viral etiology. Sampling too early or too late in the course of shedding, poor swab technique, and inhibitors in the sample can all produce false negatives. If clinical suspicion remains high, repeat sampling 24 to 48 hours later or collect a deeper airway sample.

Serology has a limited role in acute diagnosis because paired samples taken 2 to 3 weeks apart are required to demonstrate a fourfold rise in titer. A single high titer in an unvaccinated dog supports recent infection but cannot distinguish current from past exposure. Serology is most useful for retrospective confirmation in outbreak investigations and for population-level surveillance.

Management Principles

Supportive Care and Monitoring

Most dogs with uncomplicated viral respiratory infection recover with supportive care alone. The monitoring plan should track respiratory rate and effort, mucous membrane color, pulse oximetry, and appetite. Pulse oximetry readings below 94 percent on room air warrant supplemental oxygen and further diagnostic evaluation. Thoracic radiographs are indicated when fever persists beyond 48 hours, when crackles or dull lung sounds are ausculted, or when the respiratory rate exceeds 40 breaths per minute at rest.

Serial body weight and hydration status are practical indicators of progress. Dogs that refuse food and water for more than 24 hours require fluid therapy and nutritional support. The decision to hospitalize depends on the owner's ability to monitor at home, the presence of comorbidities, and the risk of household transmission to other dogs.

Antiviral Therapy

Specific antiviral therapy is not licensed for most canine respiratory viruses. Neuraminidase inhibitors such as oseltamivir have been used off-label for canine influenza virus, but the evidence for benefit is extrapolated from human and experimental animal data, and the drug is most effective when started within 48 hours of exposure. Current formularies and label references must be consulted before prescribing, and the limited evidence base should be discussed with the owner. No antiviral agent has demonstrated efficacy against canine distemper virus once clinical signs develop.

Antimicrobial Stewardship

Secondary bacterial pneumonia is the most common complication requiring antimicrobial therapy. Indications for antibiotics include persistent fever beyond 48 to 72 hours, a degenerative left shift on hematology, a cranioventral alveolar pattern on radiographs, or cytologic evidence of septic suppurative inflammation on BAL. When antibiotics are indicated, choose an agent with activity against the common canine respiratory bacteria and adjust based on culture and susceptibility results. Unnecessary antimicrobial use in uncomplicated viral infections selects for resistance and provides no clinical benefit.

Environmental Control and Biosecurity

Viral shedding begins before clinical signs appear, which complicates outbreak control. Isolation of affected dogs, dedicated examination rooms, and strict hand hygiene between patients reduce transmission. Canine influenza virus survives on surfaces for up to 48 hours, and fomites are a documented route of spread. Disinfectants with activity against enveloped viruses, including accelerated hydrogen peroxide and quaternary ammonium compounds, are appropriate for environmental decontamination. Personnel should change outerwear and footwear between isolation and general wards.

Prognosis and Long-Term Considerations

Most dogs recover fully within 2 to 3 weeks. Persistent coughing beyond 3 weeks warrants investigation for structural airway damage or secondary bacterial infection. Experimental models of influenza infection demonstrate that viral RNA remnants can persist in lung tissue and are associated with chronic airway inflammation and mucus hypersecretion, findings that support clinical observation of prolonged cough in some recovered dogs. The prognostic significance of these findings in naturally infected dogs is not fully defined.

Documentation and Communication

Record the date of onset, vaccination history, travel and boarding history, and the results of all diagnostic tests. In multi-dog households or kennels, document the index case and the chronology of subsequent cases. Clear communication with owners should cover the expected duration of shedding, the risk to other dogs, and the signs that warrant re-evaluation. For confirmed canine influenza virus, reporting to relevant state or regional animal health authorities may be required depending on jurisdiction, and the WOAH terrestrial animal health standards provide international guidance on notification and surveillance obligations.

Recognized Complications and Early Detection

Respiratory viral infections in dogs can progress beyond transient upper airway signs. The most clinically significant complications include secondary bacterial pneumonia, chronic airway inflammation, and rare neurologic involvement.

Secondary bacterial pneumonia is the complication most frequently encountered in practice. It should be suspected when a dog with viral respiratory signs develops a sudden increase in fever, lethargy, or cough productivity, or when the cough changes from dry to productive. Thoracic radiographs are the discriminating test. The presence of an alveolar pattern, particularly in the cranioventral lung lobes, supports bacterial pneumonia. Neutrophilia with a left shift on a complete blood count adds supporting evidence. Early detection depends on serial re-evaluation at 48 to 72 hour intervals during the acute phase, as deterioration can be rapid.

Chronic airway disease is a less immediate but important complication. Experimental work in mice demonstrates that influenza A virus infection can produce chronic lung disease with persistent viral RNA remnants, excess mucus production, and airway hyperreactivity for months after the acute infection has resolved Influenza A virus infection causes chronic lung disease linked to sites of active viral RNA remnants. The canine correlate is a cough that persists beyond three to four weeks after other signs have resolved. Detection relies on owner history and repeat thoracic imaging. Bronchoalveolar lavage may be indicated to differentiate persistent inflammation from low-grade bacterial infection.

Neurologic complications are rare but recognized. Respiratory viruses, including influenza and coronavirus, can spread from the respiratory tract to the central nervous system, producing encephalitis, seizures, or status epilepticus Neurologic alterations due to respiratory virus infections. In dogs, this is most classically associated with canine distemper virus, but any viral respiratory infection accompanied by behavioral change, ataxia, or seizure activity warrants neurologic evaluation and cerebrospinal fluid analysis.

Common Diagnostic Errors and Corrective Actions

The most frequent error is testing too early or too late in the course of disease. Point-of-care antigen tests for canine influenza virus have a narrow detection window and produce false negatives when viral shedding has declined. Molecular testing is more sensitive but can detect non-viable viral RNA for weeks after recovery, leading to over-diagnosis of active infection. The corrective action is to test within the first three to five days of clinical signs and to interpret positive molecular results in light of the clinical picture.

A second error is treating all respiratory signs as bacterial and prescribing antimicrobials without diagnostic support. This ignores the viral aetiology and contributes to antimicrobial resistance. The corrective action is to use the diagnostic framework to identify viral cases and reserve antimicrobials for confirmed or strongly suspected bacterial complications.

A third error is failing to consider host factors. Biological sex influences the outcome of respiratory viral infections, with males generally more susceptible to severe outcomes at younger and older ages, while females are at greater risk during reproductive years Sex differences in respiratory viral pathogenesis and treatments. In practice, this means that signalment should inform prognostic counseling and monitoring intensity, even though it does not change the initial diagnostic plan.

Limitations of the Current Evidence

The evidence base for canine respiratory virology is thinner than for human medicine. Much of the mechanistic understanding of viral pathogenesis, including the role of proinflammatory cytokines in lung injury, derives from porcine and murine models Differential production of proinflammatory cytokines in the pig lung during different respiratory virus infections. Extrapolation to dogs requires caution, particularly regarding the intensity and duration of the inflammatory response.

Expert opinion still differs on the value of routine antiviral therapy. No antiviral drug is licensed for canine respiratory viruses in most regions, and current recommendations are based on clinical judgment instead of controlled trials. Practitioners should consult current formularies and label references for any off-label use.

The role of adjunctive therapies, including probiotics, is supported mainly by human data showing reduced risk or duration of respiratory infection symptoms, but the antiviral mechanisms remain unclear Probiotics in respiratory virus infections. Canine-specific evidence is lacking, and these interventions should not replace core supportive care.

Referral, Consultation, and Reporting

Referral to a specialist is warranted when a dog fails to improve despite appropriate supportive care, when diagnostic testing is inconclusive but clinical deterioration continues, or when complications such as suspected viral encephalitis or non-resolving pneumonia require advanced diagnostics. Specialist consultation is also appropriate for kennel or shelter outbreaks where population-level management exceeds the capacity of primary care.

Laboratory involvement is indicated when molecular testing is required for strain identification or when a novel or emerging virus is suspected. Diagnostic laboratories can provide guidance on sample selection, transport conditions, and test interpretation.

Regulatory reporting obligations vary by jurisdiction. In some regions, canine influenza virus is a reportable disease, and veterinarians should be aware of local requirements through resources such as the WOAH terrestrial animal health standards and AVMA practice resources. When in doubt, contact the relevant state or national veterinary authority before releasing results to the owner.

Frequently Asked Questions

How Should I Prioritize Testing When the Owner Has Limited Financial Resources?

When resources are constrained, begin with thoracic radiographs and a complete blood count to assess disease severity and screen for bacterial complications. If a specific viral diagnosis will change management, prioritize PCR on a combined nasal and oropharyngeal swab during the first 3 to 5 days of clinical signs. Point-of-care antigen tests for canine influenza virus are less sensitive than PCR, so a negative result does not exclude infection. Reserve advanced diagnostics such as CT or bronchoalveolar lavage for patients with progressive disease or suspected lower airway involvement. Discuss the cost-benefit tradeoff explicitly with the owner, and document that financial limitations influenced the diagnostic plan.

What Do I Do When PCR Testing Is Unavailable or Results Are Delayed?

Treat empirically while awaiting results. Isolate the patient using standard respiratory precautions and initiate supportive care based on clinical severity. If canine influenza is epidemiologically plausible, inform the owner that viral shedding may continue for up to 7 days after clinical resolution. Use serial thoracic radiographs and daily temperature, appetite, and respiratory effort assessments to guide escalation of care. If the patient deteriorates despite supportive therapy, pursue bacterial culture from a lower airway sample instead of repeating viral testing. Document the testing limitation in the medical record and revisit the diagnostic plan if the clinical course diverges from expectations.

How Should I Advise Owners About Preventing Spread to Other Household Dogs?

Advise strict isolation of the affected dog for at least 7 days after clinical signs resolve, because viral shedding can persist beyond symptom resolution. Disinfect food bowls, bedding, and high-contact surfaces with accelerated hydrogen peroxide or dilute bleach solutions. Recommend that unaffected household dogs avoid shared water bowls and direct nose-to-nose contact. Discuss vaccination status with the owner, noting that ACVIM consensus statements provide guidance on canine influenza vaccination for at-risk populations. For multi-dog households, quarantine periods of 14 days are prudent for newly introduced dogs. Remind owners that indirect transmission via fomites, including human hands and clothing, is possible.

How Does My Approach Change for Kennel or Shelter Populations?

In group housing, assume widespread exposure once one case is confirmed. Test a representative sample of acutely affected dogs instead of every individual, using PCR to confirm the etiologic agent. Implement cohort isolation and halt intake of new dogs until 14 days after the last clinical case resolves. Review cleaning protocols, because many common disinfectants are ineffective against non-enveloped viruses such as canine adenovirus. Consult WOAH terrestrial animal health standards for outbreak reporting expectations in your jurisdiction. Communicate with local veterinary networks to warn nearby practices. Anticipate that secondary bacterial infections will emerge in stressed populations and adjust monitoring frequency accordingly.

What Should I Document in the Medical Record for a Suspected Viral Respiratory Infection?

Record the onset and duration of clinical signs, vaccination history, recent boarding or grooming exposure, and the results of all diagnostic tests with collection dates. Document the rationale for testing decisions, including any financial constraints discussed with the owner. Note the patient's temperature, respiratory rate and effort, lung auscultation findings, and hydration status at each visit. If antiviral therapy is considered, record the specific drug, dose, and the formulary reference consulted. Include owner education provided about isolation, shedding duration, and zoonotic potential, particularly for canine influenza virus. Document any reportable disease notifications made to public health authorities.

How Do I Explain the Difference Between Viral and Bacterial Respiratory Infection to a Client?

Use plain language while preserving accuracy. Explain that viruses cause the initial infection and that antibiotics do not kill viruses. Describe how secondary bacterial infections can develop when the respiratory tract is damaged, and that antibiotics are reserved for patients with evidence of bacterial involvement such as purulent nasal discharge, consolidation on radiographs, or degenerative left shift on blood work. Reference the MSD Veterinary Manual as a source for owner-level information about respiratory infections. Emphasize that supportive care, rest, and isolation are the primary treatments for viral infection. If the owner asks about probiotics, acknowledge that evidence in human medicine suggests possible benefit, but note that probiotic research in respiratory virus infections remains inconclusive for dogs.

Related Clinical & Scientific Guides

• Feline Hepatic Lipidosis: Nutritional and Medical Management
• Canine Respiratory Infection: Diagnostic Approach and Treatment
• Canine Inflammatory Bowel Disease: Diagnostic and Therapeutic Approach

References and Further Reading

• Neurologic Alterations Due to Respiratory Virus Infections.. 2018.
• Probiotics in respiratory virus infections.. 2014.
• Sex Differences in Respiratory Viral Pathogenesis and Treatments.. 2021.
• Differential production of proinflammatory cytokines in the pig lung during different respiratory virus infections: correlations with pathogenicity.. 1999.
• Cigarette smoke worsens lung inflammation and impairs resolution of influenza infection in mice.. 2008.
• Influenza A Virus Infection Causes Chronic Lung Disease Linked to Sites of Active Viral RNA Remnants.. 2018.
• ACVIM Consensus Statements. Journal of Veterinary Internal Medicine.
• MSD Veterinary Manual, Professional Edition. MSD Veterinary Manual.
• American Veterinary Medical Association Practice Resources. American Veterinary Medical Association.

Related Articles

• Canine Autoimmune Disease Overview: Diagnostic Considerations
• Canine Respiratory Infection: Diagnostic Approach and Treatment
• Canine Vomiting: Diagnostic Approach and Management
• Canine Lower Respiratory Disease: Diagnostic and Management Strategy
• Canine Acute Respiratory Distress Syndrome: Diagnostic Criteria and Management

This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.